EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische Studie

Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease

Haydar Frangoul iD, Josu de la Fuente iD, Yogi Chopra, Roland Meisel, Persis J Amrolia, Mattia Algeri, Akshay Sharma iD, Maria Domenica Cappellini, Selim Corbacioglu iD, Antonis Kattamis, Stephan Lobitz, Mariane de Montalembert und 11 weitere

New England Journal of Medicine · 2026

DOI: 10.1056/nejmoa2603387 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, 2026. Verfasst von Haydar Frangoul und 22 weiteren Autor:innen. Beteiligte Einrichtung: Sarah Cannon Research Institute at the Children's Hospital at TriStar Centennial, Nashville. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, beta-Thalassemia, Fetal Hemoglobin, Genetic Therapy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Vertex Pharmaceuticals Incorporated.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle Cellbeta-ThalassemiaFetal HemoglobinGenetic TherapyHematopoietic Stem Cell TransplantationRepressor ProteinsGene Therapy AgentsChildChild, PreschoolFemaleHumansMaleErythrocyte TransfusionTransplantation ConditioningTransplantation, AutologousVaso-Occlusive CrisesClustered Regularly Interspaced Short Palindromic RepeatsFollow-Up StudiesBusulfanTreatment Outcome

Substanzen

BCL11A protein, humanFetal HemoglobinRepressor Proteinsexagamglogene autotemcelBusulfan

Autor:innen und Institutionen

  • Sarah Cannon Research Institute at the Children's Hospital at TriStar Centennial, Nashville.
  • Imperial College Healthcare NHS Trust, St. Mary's Hospital, London.
  • Hospital for Sick Children, Toronto.
  • Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
  • Great Ormond Street Hospital for Children, London.
  • IRCCS Ospedale Pediatrico Bambino Gesù Rome, Rome.

ORCID-Profile: Haydar Frangoul, Josu de la Fuente, Akshay Sharma, Selim Corbacioglu, Franco Locatelli

Förderung

  • Vertex Pharmaceuticals Incorporated

Zitieren

APA

Frangoul, H., de la Fuente, J., Chopra, Y., Meisel, R., Amrolia, P. J., Algeri, M., Sharma, A., Cappellini, M. D., Corbacioglu, S., Kattamis, A., Lobitz, S., de Montalembert, M., Rondelli, D., Sheth, S., Steinberg, M. H., Walters, M. C., Boerner, K., Liu, T., Zairis, S., …, & CLIMB THAL-141 and CLIMB SCD-151 Study Groups (2026). Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2603387

Vancouver

Frangoul H, de la Fuente J, Chopra Y, Meisel R, Amrolia PJ, Algeri M, et al. Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease. New England Journal of Medicine. 2026. doi:10.1056/nejmoa2603387

BibTeX
@article{Frangoul2026,
  author = {Frangoul, Haydar and de la Fuente, Josu and Chopra, Yogi and Meisel, Roland and Amrolia, Persis J and Algeri, Mattia and Sharma, Akshay and Cappellini, Maria Domenica and Corbacioglu, Selim and Kattamis, Antonis and Lobitz, Stephan and de Montalembert, Mariane and Rondelli, Damiano and Sheth, Sujit and Steinberg, Martin H and Walters, Mark C and Boerner, Kevin and Liu, Tina and Zairis, Sakellarios and Hobbs, William and Grupp, Stephan A and Locatelli, Franco and CLIMB THAL-141 and CLIMB SCD-151 Study Groups, CLIMB THAL-141 and CLIMB SCD-151 Study Groups},
  title = {Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease},
  journal = {New England Journal of Medicine},
  year = {2026},
  doi = {10.1056/nejmoa2603387}
}
Kostenlos starten →